Timothy A. Springer, a director and significant shareholder of Cartesian Therapeutics, Inc. (NASDAQ:RNAC), has recently increased his holdings in the company. According to a recent SEC filing, Springer purchased a total of 52,189 shares of Cartesian Therapeutics’ common stock over several transactions. The shares were acquired at prices ranging from $17.3858 to $18.9996 per share, amounting to a total investment of approximately $965,020. The stock, currently trading at $19.35, has shown strong momentum with analyst targets ranging from $22 to $45. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
The transactions took place between December 19 and December 23, 2024. Following these acquisitions, Springer now directly owns 8,507,895 shares in the company, representing a significant stake in the $499.33M market cap company. Additionally, he holds indirect ownership of 330,695 shares through his wife and 529,798 shares through TAS Partners LLC, where he serves as the managing member. InvestingPro subscribers can access additional insights, including 7 more ProTips and comprehensive insider trading analysis.
In other recent news, Cartesian Therapeutics has been making headlines with significant developments in its clinical trials and business operations. The biotech firm has seen promising results from its Phase 2b trial of Descartes-08, a potential treatment for generalized myasthenia gravis (MG), demonstrating a 71% improvement in MG Composite scores in the Descartes-08 group, compared to a 25% improvement in the placebo group.
In addition, Cartesian has made a strategic move by converting its Series B Non-Voting Convertible Preferred Stock into common stock, resulting in the issuance of 23,893,525 shares of Common Stock. This decision simplifies the company’s capital structure and potentially broadens its shareholder base.
Analyst firms have shown confidence in Cartesian’s progress. BTIG initiated a Buy rating on Cartesian’s stock with a price target of $42, highlighting the company’s innovative approach in developing mRNA-based CAR-T cell therapies. H.C. Wainwright adjusted its outlook on the company, raising its price target from $41.00 to $45.00 and maintaining a Buy rating. Similarly, Mizuho (NYSE:) reaffirmed its Outperform rating, emphasizing the competitive edge of Descartes-08.
These are recent developments for Cartesian Therapeutics, reflecting the company’s continued efforts in advancing its mRNA cell therapy candidates and strategic financial planning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
